Does the media prefer ENTA or GHRS?

In the previous week, GH Research had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat GH Research's score of 0.47 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BCAX or ENTA?

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 2 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.94 beat Enanta Pharmaceuticals' score of 0.73 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AAPG or ENTA?

Enanta Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.07 -$177.71M N/A N/A Enanta Pharmaceuticals $65.32M 6.33 -$81.89M -$2.59 N/A

Does the media refer more to ENTA or HROW?

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 3 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Harrow's score of 0.72 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ENTA or AVBP?

In the previous week, ArriVent BioPharma had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for ArriVent BioPharma and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat ArriVent BioPharma's score of 0.42 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Enanta Pharmaceuticals (ENTA) Competitors

$14.22 +0.22 (+1.54%)

As of 01:43 PM Eastern

Compare

ENTA vs. GHRS, BCAX, AAPG, HROW, and AVBP

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include GH Research (GHRS), Bicara Therapeutics (BCAX), Ascentage Pharma Group International (AAPG), Harrow (HROW), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

How does Enanta Pharmaceuticals compare to GH Research?

Enanta Pharmaceuticals (NASDAQ:ENTA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Enanta Pharmaceuticals presently has a consensus target price of $20.29, suggesting a potential upside of 42.71%. GH Research has a consensus target price of $40.38, suggesting a potential upside of 43.22%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, GH Research had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for GH Research and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat GH Research's score of 0.47 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has lower revenue, but higher earnings than Enanta Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.33	-$81.89M	-$2.59	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

GH Research has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. GH Research's return on equity of -19.36% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
GH Research	N/A	-19.36%	-18.73%

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

GH Research beats Enanta Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Bicara Therapeutics currently has a consensus target price of $30.27, suggesting a potential upside of 6.97%. Enanta Pharmaceuticals has a consensus target price of $20.29, suggesting a potential upside of 42.71%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Enanta Pharmaceuticals has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Enanta Pharmaceuticals	$65.32M	6.33	-$81.89M	-$2.59	N/A

Bicara Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Bicara Therapeutics' return on equity of -35.89% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 2 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.94 beat Enanta Pharmaceuticals' score of 0.73 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has a beta of -0.54, indicating that its stock price is 154% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

Enanta Pharmaceuticals beats Bicara Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Ascentage Pharma Group International has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 163.13%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 42.71%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts plainly believe Ascentage Pharma Group International is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Ascentage Pharma Group International has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Ascentage Pharma Group International's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Enanta Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.07	-$177.71M	N/A	N/A
Enanta Pharmaceuticals	$65.32M	6.33	-$81.89M	-$2.59	N/A

In the previous week, Ascentage Pharma Group International had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Ascentage Pharma Group International and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Ascentage Pharma Group International's score of 0.31 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascentage Pharma Group International beats Enanta Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Harrow?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Harrow has a net margin of -5.57% compared to Enanta Pharmaceuticals' net margin of -89.56%. Harrow's return on equity of 19.59% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Harrow	-5.57%	19.59%	2.26%

Harrow has higher revenue and earnings than Enanta Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.33	-$81.89M	-$2.59	N/A
Harrow	$272.30M	5.74	-$5.14M	-$0.41	N/A

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 3 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat Harrow's score of 0.72 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals currently has a consensus target price of $20.29, suggesting a potential upside of 42.71%. Harrow has a consensus target price of $69.43, suggesting a potential upside of 65.50%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Harrow beats Enanta Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Enanta Pharmaceuticals (NASDAQ:ENTA) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, ArriVent BioPharma had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for ArriVent BioPharma and 3 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.73 beat ArriVent BioPharma's score of 0.42 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enanta Pharmaceuticals presently has a consensus price target of $20.29, indicating a potential upside of 42.71%. ArriVent BioPharma has a consensus price target of $43.14, indicating a potential upside of 25.40%. Given Enanta Pharmaceuticals' higher possible upside, equities analysts plainly believe Enanta Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Enanta Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.33	-$81.89M	-$2.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

ArriVent BioPharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. ArriVent BioPharma's return on equity of -48.98% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Summary

Enanta Pharmaceuticals beats ArriVent BioPharma on 9 of the 15 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$413.40M	$3.05B	$6.83B	$12.37B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	-5.49	19.59	25.82	24.27
Price / Sales	6.33	344.49	549.14	101.93
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	4.69	4.24	10.94	6.46
Net Income	-$81.89M	$64.45M	$3.58B	$336.87M
7 Day Performance	6.32%	3.32%	2.53%	0.45%
1 Month Performance	8.02%	0.66%	0.24%	-0.78%
1 Year Performance	89.53%	32.01%	35.55%	30.15%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.9429 of 5 stars	$14.22 +1.5%	$20.29 +42.7%	+86.7%	$413.40M	$65.32M	N/A	160
GHRS GH Research	3.4632 of 5 stars	$23.61 +6.9%	$40.38 +71.0%	+126.8%	$1.62B	N/A	N/A	10	News Coverage
BCAX Bicara Therapeutics	1.4693 of 5 stars	$25.00 +1.8%	$30.27 +21.1%	+208.5%	$1.61B	N/A	N/A	32	News Coverage
AAPG Ascentage Pharma Group International	4.6805 of 5 stars	$17.08 -0.3%	$46.43 +171.8%	-57.7%	$1.60B	$82.10M	N/A	600	Gap Up High Trading Volume
HROW Harrow	4.2716 of 5 stars	$42.78 +0.9%	$69.43 +62.3%	+36.2%	$1.59B	$268.68M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. GHRS, BCAX, AAPG, HROW, and AVBP

How does Enanta Pharmaceuticals compare to GH Research?

Summary

How does Enanta Pharmaceuticals compare to Bicara Therapeutics?

Summary

How does Enanta Pharmaceuticals compare to Ascentage Pharma Group International?

Summary

How does Enanta Pharmaceuticals compare to Harrow?

Summary

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. GHRS, BCAX, AAPG, HROW, and AVBP

How does Enanta Pharmaceuticals compare to GH Research?

Do analysts rate ENTA or GHRS?

Does the media prefer ENTA or GHRS?

Which has higher valuation & earnings, ENTA or GHRS?

Which has more volatility and risk, ENTA or GHRS?

Is ENTA or GHRS more profitable?

Do institutionals & insiders hold more shares of ENTA or GHRS?

Summary

How does Enanta Pharmaceuticals compare to Bicara Therapeutics?

Do analysts recommend BCAX or ENTA?

Which has higher valuation and earnings, BCAX or ENTA?

Is BCAX or ENTA more profitable?

Do insiders and institutionals have more ownership in BCAX or ENTA?

Does the media refer more to BCAX or ENTA?

Which has more risk and volatility, BCAX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Ascentage Pharma Group International?

Which has more volatility & risk, AAPG or ENTA?

Do insiders and institutionals believe in AAPG or ENTA?

Do analysts recommend AAPG or ENTA?

Is AAPG or ENTA more profitable?

Which has preferable earnings & valuation, AAPG or ENTA?

Does the media favor AAPG or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Harrow?

Is ENTA or HROW more profitable?

Which has better earnings and valuation, ENTA or HROW?

Which has more volatility & risk, ENTA or HROW?

Does the media refer more to ENTA or HROW?

Do insiders & institutionals hold more shares of ENTA or HROW?

Do analysts rate ENTA or HROW?

Summary

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Does the media prefer ENTA or AVBP?

Which has more risk & volatility, ENTA or AVBP?

Do insiders & institutionals believe in ENTA or AVBP?

Do analysts recommend ENTA or AVBP?

Which has preferable earnings & valuation, ENTA or AVBP?

Is ENTA or AVBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools